ArticleScientific reports2021
Glypican-3 targeted delivery of
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies.Cancer gene therapy · 2026Review
- Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.EJNMMI research · 2026Review
- Integrating diagnosis and therapy in hepatocellular carcinoma: advances in nanotheranostics.Frontiers in bioengineering and biotechnology · 2026Review
- Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3-Targeted Single-Domain Antibody PET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Review
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
- Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma.EJNMMI research · 2024Article
- Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma.Research square · 2024Article
- Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation.American journal of cancer research · 2024Article
- The expression of Ki-67 and Glypican -3 in hepatocellular carcinoma was evaluated by comparing DWI andFrontiers in oncology · 2023Article
- PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [European journal of nuclear medicine and molecular imaging · 2022Article
- Glypican-3-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.American journal of nuclear medicine and molecular imaging · 2022Review
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
Glypican-3 (GPC3) is a tumor associated antigen expressed by hepatocellular carcinoma (HCC) cells. This preclinical study evaluated the efficacy of a theranostic platform using a GPC3-targeting antibody αGPC3 conjugated to zirconium-89 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.